UNSPSC 51191602: Sodium chloride electrolytes

This classification denotes an electrolyte solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 451W47IQ8X, chemically known as sodium;chloride, more generally known as sodium chloride or saline, US NIH Compound Identifier 5234. European Medicines Agency schedules Sodium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12581MIG. Sodium chloride generally arises in the molecular formula CLNA.

The term 'sodium chloride' is an FDA designation, but the term COMPOUND SOLUTION OF SODIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, 1955, 9, 185-194, List 1.) SMILES: [Na+].[Cl-].

UNSPSC 51191602 Sodium chloride electrolytes is a Commodity code that encompasses chemical supply for municipal water treatment and facility operations. State and local governments procure sodium bisulfite and similar inorganic chemical commodities for water pollution control facilities, where they function as treatment agents in water reclamation and quality management processes. The issuing bodies are primarily municipal water departments and environmental utilities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, also uses this code for broader pharmaceutical and chemical product procurement across participating state and local facilities. Recent solicitations emphasize firm unit pricing, compliance with cGMP and FDA requirements where applicable, authorized wholesale distribution channels, and performance bonds or insurance coverage ranging from $1,000,000 to $5,000,000 depending on scope.

The code shows recent activity in Connecticut and Minnesota. The City of Meriden, Connecticut issued an IFB (B027-15) for sodium bisulfite chemical supply due July 29, 2026, under which contractors must maintain $1,000,000–$2,000,000 in General Liability coverage and submit performance and payment bonds prior to contract issuance. MMCAP issued an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products across Minnesota and Oregon, requiring vendors to work through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) and demonstrating pricing flexibility through flat-price or WAC-minus structures. The MMCAP contract was set to award by May 15, 2026 and run through June 30, 2028, with a 3 percent administrative fee on all purchases and performance penalties of $200–$1,500 per violation.